Report Detail
Global Liposomal Doxorubicin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4670239 |
- 22 January, 2026 |
- Global |
- 94 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Liposomal Doxorubicin market size was valued at US$ 923 million in 2025 and is forecast to a readjusted size of US$ 725 million by 2032 with a CAGR of -3.4% during review period.
Liposomal doxorubicin is a chemotherapeutic drug in which doxorubicin, a widely used anthracycline antibiotic for cancer treatment, is encapsulated within liposomes—tiny, spherical lipid-based vesicles. This liposomal formulation enhances the drug's delivery to tumor tissues, prolongs circulation time in the bloodstream, and reduces cardiotoxicity and other systemic side effects commonly associated with conventional doxorubicin. It is used to treat various cancers, including ovarian cancer, breast cancer, multiple myeloma, and Kaposi’s sarcoma, particularly in patients who are sensitive to the adverse effects of standard chemotherapy.
A key driver of the liposomal doxorubicin market is the increasing demand for safer and more effective cancer therapies that minimize systemic toxicity while maintaining therapeutic efficacy. Traditional doxorubicin, though widely used in oncology, is associated with severe adverse effects, particularly dose-limiting cardiotoxicity. The liposomal formulation addresses this issue by encapsulating doxorubicin in lipid bilayers, enabling targeted delivery to tumor sites while reducing exposure to healthy tissues. This significantly enhances the drug’s safety profile and patient tolerability, especially in long-term or combination chemotherapy regimens. The growing global burden of cancer—driven by aging populations, lifestyle changes, and better diagnostic capabilities—has led to a surge in demand for advanced oncologic treatments, further propelling the use of liposomal formulations. Additionally, the increasing adoption of personalized medicine and targeted drug delivery systems aligns well with liposomal drug technologies, positioning liposomal doxorubicin as a preferred choice in indications such as metastatic breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. Regulatory approvals and clinical evidence supporting its efficacy in both first-line and salvage therapy settings are also contributing to broader market acceptance and use.
Despite its therapeutic advantages, the liposomal doxorubicin market faces several notable challenges. One of the primary hurdles is the high cost of liposomal drug development and production, which involves complex manufacturing processes and strict quality controls to ensure stability, bioavailability, and batch consistency. This results in a significantly higher price point compared to conventional chemotherapy, which can limit accessibility—particularly in low- and middle-income countries or healthcare systems with constrained budgets. Moreover, the availability of generic liposomal doxorubicin products in some markets has led to pricing pressure and increased competition, raising concerns over market share and profit margins for originator brands like Doxil (Caelyx in Europe). Supply chain issues and past shortages of liposomal doxorubicin have also disrupted treatment continuity for patients and eroded confidence in product availability. Additionally, regulatory complexities related to bioequivalence and product substitution of liposomal formulations pose challenges for market entry and approval of generics. From a clinical perspective, while liposomal doxorubicin reduces cardiotoxicity, it may introduce other adverse effects such as palmar-plantar erythrodysesthesia (hand-foot syndrome), which can impact patient compliance. Addressing these challenges will require continued investment in formulation innovation, cost-effective manufacturing, regulatory harmonization, and real-world outcome data to support the broader adoption of liposomal chemotherapeutics.
This report is a detailed and comprehensive analysis for global Liposomal Doxorubicin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Liposomal Doxorubicin market size and forecasts, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD/Unit), 2021-2032
Global Liposomal Doxorubicin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD/Unit), 2021-2032
Global Liposomal Doxorubicin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD/Unit), 2021-2032
Global Liposomal Doxorubicin market shares of main players, shipments in revenue ($ Million), sales quantity (K Unit), and ASP (USD/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Liposomal Doxorubicin
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Liposomal Doxorubicin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Baxter International, Nippon Kayaku, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Liposomal Doxorubicin market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
5 ml
10 ml
25 ml
Market segment by Application
Breast Cancer
Liver Cancer
Kidney Cancer
Multiple Myeloma
Ovarian Cancer
Other
Major players covered
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Baxter International
Nippon Kayaku
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Liposomal Doxorubicin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Liposomal Doxorubicin, with price, sales quantity, revenue, and global market share of Liposomal Doxorubicin from 2021 to 2026.
Chapter 3, the Liposomal Doxorubicin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Liposomal Doxorubicin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Liposomal Doxorubicin market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Liposomal Doxorubicin.
Chapter 14 and 15, to describe Liposomal Doxorubicin sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Liposomal Doxorubicin Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 5 ml
- 1.3.3 10 ml
- 1.3.4 25 ml
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Liposomal Doxorubicin Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Breast Cancer
- 1.4.3 Liver Cancer
- 1.4.4 Kidney Cancer
- 1.4.5 Multiple Myeloma
- 1.4.6 Ovarian Cancer
- 1.4.7 Other
- 1.5 Global Liposomal Doxorubicin Market Size & Forecast
- 1.5.1 Global Liposomal Doxorubicin Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Liposomal Doxorubicin Sales Quantity (2021-2032)
- 1.5.3 Global Liposomal Doxorubicin Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Johnson & Johnson
- 2.1.1 Johnson & Johnson Details
- 2.1.2 Johnson & Johnson Major Business
- 2.1.3 Johnson & Johnson Liposomal Doxorubicin Product and Services
- 2.1.4 Johnson & Johnson Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Johnson & Johnson Recent Developments/Updates
- 2.2 Sun Pharmaceutical
- 2.2.1 Sun Pharmaceutical Details
- 2.2.2 Sun Pharmaceutical Major Business
- 2.2.3 Sun Pharmaceutical Liposomal Doxorubicin Product and Services
- 2.2.4 Sun Pharmaceutical Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Sun Pharmaceutical Recent Developments/Updates
- 2.3 CSPC
- 2.3.1 CSPC Details
- 2.3.2 CSPC Major Business
- 2.3.3 CSPC Liposomal Doxorubicin Product and Services
- 2.3.4 CSPC Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 CSPC Recent Developments/Updates
- 2.4 Kinyond
- 2.4.1 Kinyond Details
- 2.4.2 Kinyond Major Business
- 2.4.3 Kinyond Liposomal Doxorubicin Product and Services
- 2.4.4 Kinyond Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Kinyond Recent Developments/Updates
- 2.5 Teva
- 2.5.1 Teva Details
- 2.5.2 Teva Major Business
- 2.5.3 Teva Liposomal Doxorubicin Product and Services
- 2.5.4 Teva Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Teva Recent Developments/Updates
- 2.6 Fudan-Zhangjiang
- 2.6.1 Fudan-Zhangjiang Details
- 2.6.2 Fudan-Zhangjiang Major Business
- 2.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Product and Services
- 2.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Fudan-Zhangjiang Recent Developments/Updates
- 2.7 Zydus Cadila
- 2.7.1 Zydus Cadila Details
- 2.7.2 Zydus Cadila Major Business
- 2.7.3 Zydus Cadila Liposomal Doxorubicin Product and Services
- 2.7.4 Zydus Cadila Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Zydus Cadila Recent Developments/Updates
- 2.8 TTY Biopharma
- 2.8.1 TTY Biopharma Details
- 2.8.2 TTY Biopharma Major Business
- 2.8.3 TTY Biopharma Liposomal Doxorubicin Product and Services
- 2.8.4 TTY Biopharma Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 TTY Biopharma Recent Developments/Updates
- 2.9 Baxter International
- 2.9.1 Baxter International Details
- 2.9.2 Baxter International Major Business
- 2.9.3 Baxter International Liposomal Doxorubicin Product and Services
- 2.9.4 Baxter International Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Baxter International Recent Developments/Updates
- 2.10 Nippon Kayaku
- 2.10.1 Nippon Kayaku Details
- 2.10.2 Nippon Kayaku Major Business
- 2.10.3 Nippon Kayaku Liposomal Doxorubicin Product and Services
- 2.10.4 Nippon Kayaku Liposomal Doxorubicin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Nippon Kayaku Recent Developments/Updates
3 Competitive Environment: Liposomal Doxorubicin by Manufacturer
- 3.1 Global Liposomal Doxorubicin Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Liposomal Doxorubicin Revenue by Manufacturer (2021-2026)
- 3.3 Global Liposomal Doxorubicin Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Liposomal Doxorubicin by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Liposomal Doxorubicin Manufacturer Market Share in 2025
- 3.4.3 Top 6 Liposomal Doxorubicin Manufacturer Market Share in 2025
- 3.5 Liposomal Doxorubicin Market: Overall Company Footprint Analysis
- 3.5.1 Liposomal Doxorubicin Market: Region Footprint
- 3.5.2 Liposomal Doxorubicin Market: Company Product Type Footprint
- 3.5.3 Liposomal Doxorubicin Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Liposomal Doxorubicin Market Size by Region
- 4.1.1 Global Liposomal Doxorubicin Sales Quantity by Region (2021-2032)
- 4.1.2 Global Liposomal Doxorubicin Consumption Value by Region (2021-2032)
- 4.1.3 Global Liposomal Doxorubicin Average Price by Region (2021-2032)
- 4.2 North America Liposomal Doxorubicin Consumption Value (2021-2032)
- 4.3 Europe Liposomal Doxorubicin Consumption Value (2021-2032)
- 4.4 Asia-Pacific Liposomal Doxorubicin Consumption Value (2021-2032)
- 4.5 South America Liposomal Doxorubicin Consumption Value (2021-2032)
- 4.6 Middle East & Africa Liposomal Doxorubicin Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Liposomal Doxorubicin Sales Quantity by Type (2021-2032)
- 5.2 Global Liposomal Doxorubicin Consumption Value by Type (2021-2032)
- 5.3 Global Liposomal Doxorubicin Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Liposomal Doxorubicin Sales Quantity by Application (2021-2032)
- 6.2 Global Liposomal Doxorubicin Consumption Value by Application (2021-2032)
- 6.3 Global Liposomal Doxorubicin Average Price by Application (2021-2032)
7 North America
- 7.1 North America Liposomal Doxorubicin Sales Quantity by Type (2021-2032)
- 7.2 North America Liposomal Doxorubicin Sales Quantity by Application (2021-2032)
- 7.3 North America Liposomal Doxorubicin Market Size by Country
- 7.3.1 North America Liposomal Doxorubicin Sales Quantity by Country (2021-2032)
- 7.3.2 North America Liposomal Doxorubicin Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Liposomal Doxorubicin Sales Quantity by Type (2021-2032)
- 8.2 Europe Liposomal Doxorubicin Sales Quantity by Application (2021-2032)
- 8.3 Europe Liposomal Doxorubicin Market Size by Country
- 8.3.1 Europe Liposomal Doxorubicin Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Liposomal Doxorubicin Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Liposomal Doxorubicin Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Liposomal Doxorubicin Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Liposomal Doxorubicin Market Size by Region
- 9.3.1 Asia-Pacific Liposomal Doxorubicin Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Liposomal Doxorubicin Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Liposomal Doxorubicin Sales Quantity by Type (2021-2032)
- 10.2 South America Liposomal Doxorubicin Sales Quantity by Application (2021-2032)
- 10.3 South America Liposomal Doxorubicin Market Size by Country
- 10.3.1 South America Liposomal Doxorubicin Sales Quantity by Country (2021-2032)
- 10.3.2 South America Liposomal Doxorubicin Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Liposomal Doxorubicin Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Liposomal Doxorubicin Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Liposomal Doxorubicin Market Size by Country
- 11.3.1 Middle East & Africa Liposomal Doxorubicin Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Liposomal Doxorubicin Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Liposomal Doxorubicin Market Drivers
- 12.2 Liposomal Doxorubicin Market Restraints
- 12.3 Liposomal Doxorubicin Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Liposomal Doxorubicin and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Liposomal Doxorubicin
- 13.3 Liposomal Doxorubicin Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Liposomal Doxorubicin Typical Distributors
- 14.3 Liposomal Doxorubicin Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Liposomal Doxorubicin. Industry analysis & Market Report on Liposomal Doxorubicin is a syndicated market report, published as Global Liposomal Doxorubicin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Liposomal Doxorubicin market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
